3. Published numerical data from trials Magill 1995.

Changes from baseline in symptoms
	median reductions (interquartile range)
	progesterone	placebo	significance
highest scoring symptom per protocol
cycle 1 (n=50 /43)	‐9 (‐16 to ‐5)	‐4 (‐12 to 0)	P<0.01
cycle 2 (n=49/43)	‐9 (15 to ‐6)	‐5 (‐10 to ‐1)	P<0.01
cycle 3 (n=42/38)	‐10 (‐16 to ‐5)	‐8 (‐13 to ‐2)
cycle 4 (n=41/31)	‐10 (‐16 to ‐5)	‐5 (‐12 to 0)	P< 0.05
highest scoring sympton in intention to treat analysis	not recorded	not recorded	not recorded
average symptom score per protocol
cycle 1(n=50 /43)	‐7 (‐12 to ‐4)	‐4 (‐10 to 0)	P<0.01
cycle 2 (n=49/43	‐7 (‐12 to ‐5)	‐5 (‐9 to 0)	P< 0.05
cycle 3 (n=42/38)	‐10 (‐12 to ‐5)	‐6 (‐11 to ‐2)	P< 0.05
cycle 4 (41/31)	‐10 (‐14 to ‐2)	‐4 (‐10 to 0)
average syptom score in intention to treat analysis
cycle 1 (n=73/57)	‐5 (‐9 to ‐1)	‐2 (‐7 to 2)	P< 0.05
cycle 2 (n=66/57)	‐5 (‐10 to ‐2)	‐3 (‐8 to 1)
cycle 3 (n=58/51)	‐6 (‐10 to 0)	‐3 (‐8 to 1)
cycle 4 (n=57/43)	‐4 (‐10 to 1)	‐4 (‐10 to 2)